AI-Designed Drug Rentosertib Shows Potential for Biological Age Reversal

Insilico Medicine's experimental lung disease drug, rentosertib, demonstrated the ability to reduce biological age markers in a midstage study of 42 patients.

The findings, published in Nature Biotechnology on Monday, showed that patients treated with the drug improved across six different aging clocks compared to a placebo group.

CEO Alex Zhavoronkov cautioned that the results are early-stage and the long-term health impacts of the AI-discovered treatment on larger populations remain unknown.